Why Is PACIRA BIOSCIENCES I (PCRX) Stock Up Today?
By the Top Tier Newswire AI Desk · October 8, 2026 at 9:52 AM ET · reviewed against 9 wire stories
PACIRA BIOSCIENCES I (PCRX) is up +44.01% in the latest session. Our newswire has captured 9 stories on PCRX across 7 sources in the last 36 hours, with AI sentiment reading bullish (avg 62/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Pacira BioSciences (PCRX) shares surged 44.01% to $36.29 on Wednesday. The primary driver was the announcement that Viatris has agreed to acquire the pain-drug maker in an all-cash transaction valued at $1.65 billion. The deal prices the stock at $36.50 per share, representing a significant premium to the prior close.
What Happened
Viatris disclosed the agreement to acquire Pacira BioSciences, aiming to expand its innovative medicines portfolio and establish leadership in non-opioid pain therapies. The acquisition includes two marketed, patent-protected, high-margin U.S. brands: EXPAREL and ZILRETTA. Viatris expects the transaction to close by the end of 2026 and stated that the deal is expected to be immediately accretive to its financial guidance. Pacira BioSciences filed a Form 8-K with the SEC on October 8, 2026, detailing the entry into this material definitive agreement. The company also recently announced an exclusive agreement with Molteni Farmaceutici to commercialize EXPAREL in Europe, for which Pacira will receive an upfront payment plus royalties. Truist Securities maintained a Buy rating on the stock and raised its price target to $31 from $30, though this target remains below the acquisition price.
What The Data Shows
Pacira’s market capitalization stands at $987.0 million, with a trailing P/E of 71.6. The company reported revenue growth of 5.7% over the trailing twelve months and a net margin of 2.0%. The stock’s beta is 0.25, indicating low volatility relative to the broader market. Intraday, the stock opened at $25.72, a 2.1% gap up from the previous close of $25.20. Trading was halted at 7:40 AM ET pending news, with quotations resuming at 8:00 AM ET. The session high reached $36.40 at 8:15 AM ET, while the low was $25.72 at 7:25 AM ET. Volume reached 12.7 million shares, which is 23.0 times the three-month daily average. Over the last eight sessions, the stock had moved down 0.7% from $25.39 to $25.20. The 52-week range is $18.80 to $27.66, and the stock printed two fresh 52-week lows on October 8, 2026. Recent insider activity includes one sale by Chief Medical Officer Jonathan Slonin on August 17, 2026, totaling $71,000.
What To Watch
The deal is expected to close by the end of 2026. Investors will monitor the integration of EXPAREL and ZILRETTA into Viatris’s international infrastructure and the realization of the stated accretion to financial guidance.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
PCRX · today's session (5-min) · +44.23% vs prior close · updated 3:43 PM ETAI sentiment, last 36h · averaged over 9 stories · 62/100 bullish
The headlines behind the move
Story flow · 8 stories on the wire, last 36h · hover or tap a dot for the headline
6h agoSEC 8-KNEUTRAL 53General
Pacira BioSciences, Inc. (PCRX) files 8-K
Filed: 2026-10-08 AccNo: 0001104659-26-114571 Size: 1 MB Item 1.01: Entry into a Material Definitive Agreement Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
6h agoWSJBULLISH 64M&A
Viatris to Buy Pacira BioSciences for $1.65 Billion
Viatris has agreed to buy pain-drug maker Pacira BioSciences for $1.65 billion in a deal that expands the healthcare company’s medicines portfolio.
7h agoMarketChameleonBULLISH 64M&A
Viatris targets non-opioid pain leadership with a $1.65 billion Pacira deal and two patent-protected U.S. brands
October 8, 2026
Viatris announced an agreement to acquire Pacira BioSciences in an all-cash deal valued at $1.65 billion, aiming to expand its innovative medicines strategy and build leadership in non-opioid pain therapies. The transaction adds Pacira’s marketed U.S. brands EXPAREL and ZILRETTA, with Pacira reporting approximately $746 million in trailing revenue and $177 million in adjusted EBITDA through June 30, 2026. Viatris said the deal is expected to close by the end of 2026 and be immediately…
7h agoThe FlyBULLISH 64M&A
Viatris: Pacira deal expected to be immediately accretive to financial guidance
7h agoSeeking AlphaBULLISH 64M&A
Viatris to buy Pacira BioSciences for $36.50/share in cash
Viatris to acquire Pacira for $36.50/share in a $1.65B cash deal, expected to close by end of 2026.
7h agoThe FlyBULLISH 64M&A
Viatris to acquire Pacira for $36.50 per share in cash, or $1.65B
7h agoPR NewswireBULLISH 67M&A
Viatris Agrees to Acquire Pacira BioSciences, Advancing Its Innovative Medicines Strategy and Becoming a Leader in Non-Opioid Pain Therapies
Adds Two Marketed, Patent-Protected, High-Margin Medicines in the U.S., EXPAREL® and ZILRETTA®, and Expects to Expand the Products' Reach Across Selected Markets Within Its International Infrastructure Expands U.S. Innovative Medicines Commercial, Market Access, Medical Affairs and Global...
1d agoThe FlyBULLISH 63Analyst
Pacira price target raised to $31 from $30 at Truist
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →